Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) Interest & Investment Income (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Interest & Investment Income for 15 consecutive years, with $578000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income fell 81.6% to $578000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $4.7 million, a 59.45% decrease, with the full-year FY2024 number at $11.3 million, up 17.45% from a year prior.
  • Interest & Investment Income was $578000.0 for Q3 2025 at Usana Health Sciences, down from $619000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $3.1 million in Q3 2024 to a low of $487000.0 in Q4 2021.
  • A 5-year average of $1.5 million and a median of $918000.0 in 2022 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 230.46% in 2023, then crashed 81.6% in 2025.
  • Usana Health Sciences' Interest & Investment Income stood at $487000.0 in 2021, then skyrocketed by 199.59% to $1.5 million in 2022, then surged by 99.11% to $2.9 million in 2023, then dropped by 5.75% to $2.7 million in 2024, then crashed by 78.89% to $578000.0 in 2025.
  • Per Business Quant, the three most recent readings for USNA's Interest & Investment Income are $578000.0 (Q3 2025), $619000.0 (Q2 2025), and $723000.0 (Q1 2025).